EORTC trial 20012 (P. Carde, N. Mounier): an Intergroup (EORTC, Lymphoma Study Association (LYSA), Australasian Lymphoma Leukemia Group (ALLG), National Cancer Research Institute Lymphoma Group (NCRI LYG), Grup per l’Estudi dels Limfomes de Catalunya i Balears (GELCAB), National Cancer Institute of Canada (NCIC), and Nordic Lymphoma Group (NLG)) phase III randomized trial comparing BEACOPP (cyclophos-phamide, doxorubicin, etoposide, procarbazine, prednisone, bleomycin, vincristine; four cycles escalated + four cycles baseline) versus ABVD (doxorubicin, bleomycin, vinblastin, dacarbazine; eight cycles) in high risk stage III & IV HL having reached complete remission after six cycles. The required number of patients was reached in January 2010. The final results were presented at ASCO 2012 (oral), and this was selected to be included in the Best of ASCO program.
EORTC 20051- H10 trial (J.M.M. Raemaekers): an Intergroup (EORTC, LYSA, and the Italian Lymphoma Foundation (FIL)) phase III randomized trial on early 18F fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) scan guided treatment adaptation versus standard combined modality treatment in patients with supra-diaphragmatic stage I/II HL. An interim analysis of efficacy was performed and reviewed in June 2010 by the EORTC Independent Data Monitoring Committee. The primary objective of the study (can radiotherapy be avoided in early PET-negative patients?) was unlikely to be met, so this part of the study was closed. The study remained open to accrual until June 2011 for the secondary objective (Is intensified treatment superior to standard treatment in early PET positive patients?). Two additional questions based on the PET scan after two cycles of adriamycin (doxorubicin), bleomycin, vinblastine, and dacarbazine (ABVD) are being investigated, namely a comparison of visual and quantitative assessment of the PET scan and the incidence of positive PET scan in relation to the presence or absence of bulky mediastinal disease.
EORTC 20982- H9 trial (J. Thomas and C. Fermé; EORTC and LYSA). Two articles, “Comparison of 36 Gy, 20 Gy or no involved field-radiotherapy after six cycles of EBVP chemotherapy in early-stage Hodgkin’s Lymphoma with a favorable prognosis: Results of the EORTC–GELA H9-F intergroup randomized trial” and “Combined ABVD or BEACOPP and involved-field radiotherapy in early-stage Hodgkin’s Lymphoma with an unfavorable prognosis: Results of the EORTC–GELA H9-U intergroup randomized trial”, have been finalized and have been submitted for publication.
Long-term survivorship in European patients treated for HL (M. Henry-Amar): The EORTC Lymphoma Group has included more than 6000 patients in EORTC/GELA HL trials over the last 45 years. The purpose of this cross-sectional study is to evaluate the consequences of the disease and its treatment on social, professional and private life as well as detection of late side effects in survivors enrolled during this period of time. In the first part of the project which was completed in October 2010, 3604 living patients received a Life Situation Questionnaire which included questions in six categories: general, parenthood, education/work, health, social life, and support. Survivors of HL had slightly but significantly fewer children after treatment than matched general population controls. The difference concerned only survivors who had children before treatment and appears to have more personal than biologic reasons. The chance of successful posttreatment parenthood was 76%. Non-alkylating chemotherapy carries little to no excess risk of premature ovarian failure (POF). Dose-response relationships for alkylating agents and age at treatment are both linear. Even women ultimately experiencing POF can become mothers after treatment in one-fourth of cases. Three hundred and sixty-three out of 902 men (40%) cryopreserved semen before the start of potentially gonadotoxic treatment. The likelihood of semen cryopreservation was influenced by age, treatment period, disease stage, treatment modality and education level. Seventy eight of 363 men (21%) used their cryopreserved semen. Forty-eight out of 258 men (19%) who had children after HL treatment became a father using cryopreserved semen.
A pilot study was performed to investigate whether tumor cell Epstein Barr virus involvement is associated with fatigue in Hodgkin lymphoma survivors. There was no association in this pilot study.